Kymera Therapeutics (KYMR) and Its Competitors Head to Head Survey

Kymera Therapeutics (NASDAQ:KYMR) is one of 844 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Kymera Therapeutics to similar businesses based on the strength of its institutional ownership, dividends, earnings, risk, valuation, analyst recommendations and profitability.

Earnings & Valuation

This table compares Kymera Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kymera Therapeutics	$39.21 million	-$311.35 million	-34.98
Kymera Therapeutics Competitors	$689.45 million	$10.37 million	-10.05

Kymera Therapeutics’ rivals have higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Kymera Therapeutics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kymera Therapeutics	1	2	23	1	2.89
Kymera Therapeutics Competitors	9773	15031	45238	1571	2.54

Kymera Therapeutics currently has a consensus price target of $137.92, suggesting a potential upside of 8.92%. As a group, “Biotechnology” companies have a potential upside of 96.19%. Given Kymera Therapeutics’ rivals higher probable upside, analysts clearly believe Kymera Therapeutics has less favorable growth aspects than its rivals.

Risk & Volatility

Kymera Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500. Comparatively, Kymera Therapeutics’ rivals have a beta of 1.11, suggesting that their average stock price is 11% more volatile than the S&P 500.

Profitability

This table compares Kymera Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kymera Therapeutics	-285.33%	-22.65%	-20.73%
Kymera Therapeutics Competitors	-9,054.31%	-198.21%	-30.53%

Insider & Institutional Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 16.0% of Kymera Therapeutics shares are owned by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Kymera Therapeutics beats its rivals on 8 of the 13 factors compared.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.